Immunovant Net Worth
Immunovant Net Worth Breakdown | IMVT |
Immunovant Net Worth Analysis
Immunovant's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immunovant's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immunovant's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immunovant's net worth analysis. One common approach is to calculate Immunovant's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immunovant's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immunovant's net worth. This approach calculates the present value of Immunovant's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immunovant's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immunovant's net worth. This involves comparing Immunovant's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immunovant's net worth relative to its peers.
Enterprise Value |
|
To determine if Immunovant is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunovant's net worth research are outlined below:
| Immunovant generated a negative expected return over the last 90 days | |
| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Immunovant has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Have Immunovant Insiders Been Selling Stock |
Immunovant uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunovant. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunovant's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Immunovant Target Price Consensus
Immunovant target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Immunovant's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 16 | Strong Buy |
Most Immunovant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Immunovant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Immunovant, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationImmunovant Target Price Projection
Immunovant's current and average target prices are 28.20 and 43.85, respectively. The current price of Immunovant is the price at which Immunovant is currently trading. On the other hand, Immunovant's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Immunovant Market Quote on 29th of November 2024
Target Price
Analyst Consensus On Immunovant Target Price
Know Immunovant's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunovant is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunovant backward and forwards among themselves. Immunovant's institutional investor refers to the entity that pools money to purchase Immunovant's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.5 M | Paradigm Biocapital Advisors Lp | 2024-09-30 | 1.4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | Baker Bros Advisors Lp | 2024-09-30 | 1.2 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.2 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Logos Global Management Lp | 2024-06-30 | 1.1 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.1 M | Fmr Inc | 2024-09-30 | 12.5 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
Follow Immunovant's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.22 B.Market Cap |
|
Project Immunovant's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.46) | (0.02) | |
| Return On Equity | (0.42) | (0.02) |
When accessing Immunovant's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immunovant's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunovant's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immunovant's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunovant. Check Immunovant's Beneish M Score to see the likelihood of Immunovant's management manipulating its earnings.
Evaluate Immunovant's management efficiency
Immunovant has return on total asset (ROA) of (0.5454) % which means that it has lost $0.5454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9217) %, meaning that it created substantial loss on money invested by shareholders. Immunovant's management efficiency ratios could be used to measure how well Immunovant manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.0011 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. Total Current Liabilities is likely to drop to about 27.1 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 386.8 M in 2024| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (13.82) | (5.03) | |
| Price Book Value Ratio | 7.07 | 5,826 | |
| Enterprise Value Multiple | (13.82) | (5.03) | |
| Price Fair Value | 7.07 | 5,826 | |
| Enterprise Value | 1.4 B | 1.4 B |
The leadership approach at Immunovant's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Return On Equity (0.92) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunovant insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunovant's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunovant insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunovant Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 20th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Immunovant Earnings per Share Projection vs Actual
Immunovant Corporate Management
| MD MBA | Executive Board | Profile | |
| Jay Stout | Chief Officer | Profile | |
| Mark JD | Chief Secretary | Profile | |
| Julia Butchko | Chief Officer | Profile | |
| Andy Deig | Senior Finance | Profile | |
| Mark Levine | Chief Secretary | Profile | |
| Lauren MBA | Vice Marketing | Profile |
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.